These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Clinical pharmacokinetics: results and problems]. Simon P Ann Pharm Fr; 1983; 41(2):107-14. PubMed ID: 6651158 [No Abstract] [Full Text] [Related]
23. Drug interactions. Scott A J Ir Med Assoc; 1974 Jun; 67(11):299-305. PubMed ID: 4841758 [No Abstract] [Full Text] [Related]
24. Trends in new drug interactions for pharmaceutical products in Japan. Yoshida N; Yamada A; Mimura Y; Kawakami J; Adachi I Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):421-7. PubMed ID: 16331581 [TBL] [Abstract][Full Text] [Related]
25. [Editorial: A second life for medicine (author's transl)]. Glasson B Schweiz Rundsch Med Prax; 1974 May; 63(18):543-4. PubMed ID: 4831242 [No Abstract] [Full Text] [Related]
27. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
28. An approach to the problem of drug interactions. Whiting B J R Nav Med Serv; 1976; 62(2):99-102. PubMed ID: 966202 [No Abstract] [Full Text] [Related]
29. [Data for the modeling of drug-receptor interaction, taking into consideration additives or combined active ingredients in the formulation]. Bozzay J; Békefi E; Dávid A; Rusznák I Acta Pharm Hung; 1983 May; 53(3):97-105. PubMed ID: 6880768 [No Abstract] [Full Text] [Related]
30. A rational approach to adverse drug interactions. Myslinski NR J Baltimore Coll Dent Surg; 1980 Sep; 34(1):5-10. PubMed ID: 6938507 [No Abstract] [Full Text] [Related]
31. [Chiral compounds and their pharmacologic effects]. Slováková A; Hutt AJ Ceska Slov Farm; 1999 May; 48(3):107-12. PubMed ID: 10422348 [TBL] [Abstract][Full Text] [Related]
34. The future of antihypertensive treatment. Israili ZH; Hernández-Hernández R; Valasco M Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579 [TBL] [Abstract][Full Text] [Related]
35. Clinically important potential drug-drug interactions in outpatient settings. Aparasu R; Baer R; Aparasu A Res Social Adm Pharm; 2007 Dec; 3(4):426-37. PubMed ID: 18082877 [TBL] [Abstract][Full Text] [Related]
36. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic. Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038 [TBL] [Abstract][Full Text] [Related]
37. [When do drug combinations show the danger of side effects]. Tschudi-Steiner I Pharm Acta Helv; 1975; 50(11):415-20. PubMed ID: 1208612 [No Abstract] [Full Text] [Related]
38. [Mechanisms of drug interactions]. Simard-Savoie S Union Med Can; 1987 Feb; 116(2):125-30. PubMed ID: 3564186 [No Abstract] [Full Text] [Related]
39. Network analysis of adverse drug interactions. Takarabe M; Okuda S; Itoh M; Tokimatsu T; Goto S; Kanehisa M Genome Inform; 2008; 20():252-9. PubMed ID: 19425139 [TBL] [Abstract][Full Text] [Related]
40. Relating pharmacology to clinical practice: the pharmacologic basis of rational polypharmacy. Ferrendelli JA Neurology; 1995 Mar; 45(3 Suppl 2):S12-6. PubMed ID: 7898740 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]